The Persistent Generalized Muscle Contraction in Siblings with Molybdenum Cofactor Deficiency Type A

Abstract

Molybdenum cofactor deficiency (MoCD) is a rare autosomal recessive metabolic disease with severe neurological symptoms. Most disease-causing mutations are found in the MOCS1 gene, corresponding to MoCD type A (MoCD-A). There have been few reports describing the long-term detailed neurological features with MoCD-A because most patients do not survive childhood. We describe the clinical, radiologic, biochemical, and genetic data of two patients (female siblings aged 26 and 22 years) with MoCD-A. Both patients presented with feeding difficulties, neurological deterioration, and persistent generalized muscle contraction which can be easily confused with status dystonicus. Biochemical tests revealed low serum uric acid, elevated urinary sulfocysteine, and xanthine. Brain magnetic resonance imaging (MRI) revealed distinctive abnormalities in the bilateral caudate nucleus, putamen, globus pallidus, and cerebral white matter adjacent to the cortex. The thalamus was relatively unaffected. Genetic testing identified a novel homozygous variant in the MOCS1 gene (c.949C > T p.Arg317Cys). Biochemical results supported the hypothesis that this genetic variant is a pathological mutation. When there are symptoms of persistent generalized muscle contraction and characteristic MRI findings, MoCD should be considered as a differential diagnosis.

Keywords

molybdenum cofactor deficiency - MOCS1 - status dystonicus - persistent generalized muscle contraction

• References

• 1 Schwarz G. Molybdenum cofactor and human disease. Curr Opin Chem Biol 2016; 31: 179-187
• 2 Reiss J, Hahnewald R. Molybdenum cofactor deficiency: mutations in GPHN, MOCS1, and MOCS2. Hum Mutat 2011; 32 (01) 10-18
• 3 Atwal PS, Scaglia F. Molybdenum cofactor deficiency. Mol Genet Metab 2016; 117 (01) 1-4
• 4 Mechler K, Mountford WK, Hoffmann GF, Ries M. Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency. Genet Med 2015; 17 (12) 965-970
• 5 Schwahn BC, Van Spronsen FJ, Belaidi AA. , et al. Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study. Lancet 2015; 386 (10007): 1955-1963
• 6 Iwama K, Iwata A, Shiina M. , et al. A novel mutation in SLC1A3 causes episodic ataxia. J Hum Genet 2018; 63 (02) 207-211
• 7 Nagappa M, Bindu PS, Taly AB, Sinha S, Bharath RD. Child neurology: molybdenum cofactor deficiency. Neurology 2015; 85 (23) e175-e178
• 8 Vijayakumar K, Gunny R, Grunewald S. , et al. Clinical neuroimaging features and outcome in molybdenum cofactor deficiency. Pediatr Neurol 2011; 45 (04) 246-252
• 9 Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. ; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111 (01) e89-e97
• 10 Ruiz-Lopez M, Fasano A. Rethinking status dystonicus. Mov Disord 2017; 32 (12) 1667-1676
• 11 Maruyama K, Iai M, Arai H, Yokochi K. [Clinical profile of persistent generalized muscle contraction following the insult of developing brain] (in Japanese). No To Hattatsu 2014; 46 (01) 10-15
• 12 Hysinger EB, Panitch HB. Paediatric tracheomalacia. Paediatr Respir Rev 2016; 17: 9-15
• 13 Stence NV, Coughlin II CR, Fenton LZ, Thomas JA. Distinctive pattern of restricted diffusion in a neonate with molybdenum cofactor deficiency. Pediatr Radiol 2013; 43 (07) 882-885
• 14 Hinderhofer K, Mechler K, Hoffmann GF, Lampert A, Mountford WK, Ries M. Critical appraisal of genotype assessment in molybdenum cofactor deficiency. J Inherit Metab Dis 2017; 40 (06) 801-811
• 15 Mayr SJ, Sass JO, Vry J. , et al. A mild case of molybdenum cofactor deficiency defines an alternative route of MOCS1 protein maturation. J Inherit Metab Dis 2018; 41 (02) 187-196